Connection

Francis Spinale to Ventricular Function, Left

Back to Details
This is a "connection" page, showing publications Francis Spinale has written about Ventricular Function, Left.
Francis Spinale
Connection Strength
7.915
Ventricular Function, Left
  1. Ubiquitin ligase Wwp1 gene deletion attenuates diastolic dysfunction in pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol. 2021 11 01; 321(5):H976-H984.
    View in: PubMed
    Score: 0.592
  2. The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. Am J Physiol Heart Circ Physiol. 2020 10 01; 319(4):H765-H774.
    View in: PubMed
    Score: 0.548
  3. Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H958-H967.
    View in: PubMed
    Score: 0.474
  4. Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H814-H825.
    View in: PubMed
    Score: 0.473
  5. Institution of localized high-frequency electrical stimulation targeting early myocardial infarction: Effects on left ventricle function and geometry. J Thorac Cardiovasc Surg. 2018 08; 156(2):568-575.
    View in: PubMed
    Score: 0.463
  6. Intracoronary delivery of recombinant TIMP-3 after myocardial infarction: effects on myocardial remodeling and function. Am J Physiol Heart Circ Physiol. 2017 Oct 01; 313(4):H690-H699.
    View in: PubMed
    Score: 0.443
  7. Sonomicrometry-Based Analysis of Post-Myocardial Infarction Regional Mechanics. Ann Biomed Eng. 2016 12; 44(12):3539-3552.
    View in: PubMed
    Score: 0.413
  8. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
    View in: PubMed
    Score: 0.351
  9. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
    View in: PubMed
    Score: 0.319
  10. Diversity of myocardial interstitial proteolytic pathways: gene deletion reveals unexpected consequences. Circulation. 2011 Nov 08; 124(19):2052-5.
    View in: PubMed
    Score: 0.298
  11. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.292
  12. Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. Am J Physiol Heart Circ Physiol. 2010 Dec; 299(6):H1947-58.
    View in: PubMed
    Score: 0.277
  13. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation. 2010 Jul 06; 122(1):20-32.
    View in: PubMed
    Score: 0.271
  14. Short-term disruption in regional left ventricular electrical conduction patterns increases interstitial matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H217-24.
    View in: PubMed
    Score: 0.269
  15. Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model. Anesth Analg. 2009 Feb; 108(2):399-406.
    View in: PubMed
    Score: 0.246
  16. Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg. 2008 Aug; 86(2):568-75.
    View in: PubMed
    Score: 0.238
  17. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res. 2005 May 27; 96(10):1110-8.
    View in: PubMed
    Score: 0.190
  18. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
    View in: PubMed
    Score: 0.163
  19. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1288-95.
    View in: PubMed
    Score: 0.153
  20. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
    View in: PubMed
    Score: 0.135
  21. Speckle-Tracking Echocardiography Enables Model-Based Identification of Regional Stiffness Indices in the Left Ventricular Myocardium. Cardiovasc Eng Technol. 2020 04; 11(2):176-187.
    View in: PubMed
    Score: 0.132
  22. Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling. Circ Cardiovasc Imaging. 2019 11; 12(11):e009055.
    View in: PubMed
    Score: 0.130
  23. Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy. Am J Physiol Heart Circ Physiol. 2018 11 01; 315(5):H1443-H1452.
    View in: PubMed
    Score: 0.119
  24. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2015 Jun 01; 308(11):H1391-401.
    View in: PubMed
    Score: 0.094
  25. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.076
  26. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol. 2011 Oct; 301(4):H1656-66.
    View in: PubMed
    Score: 0.072
  27. Hemodynamics and myocardial blood flow patterns after placement of a cardiac passive restraint device in a model of dilated cardiomyopathy. J Thorac Cardiovasc Surg. 2011 Nov; 142(5):1038-45.
    View in: PubMed
    Score: 0.071
  28. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009 Sep 15; 120(11 Suppl):S220-9.
    View in: PubMed
    Score: 0.064
  29. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.064
  30. Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol. 2007 Oct; 293(4):C1362-73.
    View in: PubMed
    Score: 0.055
  31. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.
    View in: PubMed
    Score: 0.051
  32. Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation. 2005 Aug 30; 112(9):1274-83.
    View in: PubMed
    Score: 0.049
  33. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
    View in: PubMed
    Score: 0.046
  34. Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1892-9.
    View in: PubMed
    Score: 0.043
  35. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003 Oct 07; 108(14):1753-9.
    View in: PubMed
    Score: 0.042
  36. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.041
  37. Interpretable machine learning predicts cardiac resynchronization therapy responses from personalized biochemical and biomechanical features. BMC Med Inform Decis Mak. 2022 10 31; 22(1):282.
    View in: PubMed
    Score: 0.040
  38. Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H798-H805.
    View in: PubMed
    Score: 0.038
  39. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):636-46.
    View in: PubMed
    Score: 0.025
  40. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol. 2008 Jan 29; 51(4):476-86.
    View in: PubMed
    Score: 0.014
  41. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.014
  42. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006 Sep; 318(3):966-73.
    View in: PubMed
    Score: 0.013
  43. Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation. 2004 Oct 05; 110(14):e333-6.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.